Quanterix reports insurance coverage and clinical data for multiplex Alzheimer's blood test (bioanalysis-zone.com)

• Anthem Blue Cross and Blue Shield established commercial coverage for LucentAD Complete from July 2026.
• Validation study in 1,802 patients showed 90% agreement with amyloid PET/CSF and threefold fewer indeterminate results.
• The five-analyte test measures p-tau217, Aβ42/40, GFAP, and NfL using Simoa digital ELISA.
• Data presented at AAIC 2026 highlight multi-analyte advantage over single-biomarker approaches.

"Quanterix announced commercial coverage of its LucentAD Complete blood test by Anthem Blue Cross and Blue Shield, and presented new validation data showing 90% agreement with amyloid PET/CSF testing and a threefold reduction in inconclusive results compared to p-tau217 alone. The five-analyte ATN(I) assay uses Simoa digital ELISA technology to measure p-tau217, Aβ42/40, GFAP, and NfL."